Scarica l'app Stockscreener
2.21
0.23%
0.010
Precedente Chiudi:
$2.20
Aprire:
$2.2
Volume 24 ore:
624.84K
Relative Volume:
0.31
Capitalizzazione di mercato:
$474.18M
Reddito:
$314.00K
Utile/perdita netta:
$-40.23M
Rapporto P/E:
-7.8929
EPS:
-0.28
Flusso di cassa netto:
$-84.71M
1 W Prestazione:
-5.36%
1M Prestazione:
+7.04%
6M Prestazione:
+76.40%
1 anno Prestazione:
+69.62%
Intervallo 1D:
$2.1747
$2.24
Intervallo di 1 settimana:
$2.00
$2.51
Portata 52W:
$1.03
$2.64
Atai Life Sciences N V Stock (ATAI) Company Profile
Nome
Atai Life Sciences N V
Settore
Industria
Telefono
49 89 2153 9035
Indirizzo
WALLSTRASSE 16, BERLIN
Confronta ATAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
2.21 | 474.18M | 314.00K | -40.23M | -84.71M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.24 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.69 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
558.23 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
257.65 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-03 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
| 2021-11-11 | Iniziato | ROTH Capital | Buy |
| 2021-10-18 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-01 | Iniziato | Jefferies | Buy |
| 2021-07-13 | Iniziato | Berenberg | Buy |
| 2021-07-13 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-13 | Iniziato | Cantor Fitzgerald | Buy |
| 2021-07-13 | Iniziato | Citigroup | Buy |
| 2021-07-13 | Iniziato | Cowen | Outperform |
| 2021-07-13 | Iniziato | Credit Suisse | Outperform |
| 2021-07-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Atai Life Sciences N V Borsa (ATAI) Ultime notizie
ATAI Sees Potential Boost from U.S. Policy Shift on Psychedelics - GuruFocus
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire Inc.
ATAI’s Stock Dilemma: ATAI Life Sciences N.V’s Market Performance and Outlook - investchronicle.com
SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Highs and Lows - investchronicle.com
Atai Life Sciences (ATAI) Garnered a Buy Rating and $12 Target | ATAI Stock News - GuruFocus
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice - Yahoo Finance
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Lucid Capital Markets initiates coverage on atai Life Sciences stock By Investing.com - Investing.com Nigeria
ATAI Gains Buy Rating and Price Target from Lucid Capital | ATAI Stock News - GuruFocus
Lucid Capital Markets initiates coverage on atai Life Sciences stock - Investing.com
ATAI and Beckley Psytech Set to Merge in Strategic All-Share Dea - GuruFocus
Regeneron makes obesity push; Atai, Alto ink brain drug deals - Yahoo Finance
Atai Life Sciences Merges With Beckley Psytech In Major Shakeup - Finimize
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders - Morningstar
H.C. Wainwright maintains buy rating on atai Life Sciences stock By Investing.com - Investing.com India
H.C. Wainwright maintains buy rating on atai Life Sciences stock - Investing.com
Atai in $370M merger deal with psychedelic drug specialist Beckley - BioWorld MedTech
atai Life Sciences (ATAI) Merges with Beckley Psytech for Psyche - GuruFocus
atai Life Sciences and Beckley Psytech merging - Seeking Alpha
Atai Life Sciences, Beckley Psytech to Merge in All-Stock Transaction - marketscreener.com
Transcript : Atai Life Sciences N.V., Beckley Psytech LimitedM&A Call - marketscreener.com
Thiel-Backed Psychedelic Drugmaker Atai to Combine With Beckley - Bloomberg
ATAI and Beckley Psytech Plan Merger in Strategic All-Share Deal | ATAI Stock News - GuruFocus
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies - Yahoo Finance
ATAI Life Sciences stock soars on Beckley Psytech merger deal By Investing.com - Investing.com UK
Beckley Psytech & atai Life Sciences to combine expertise in pivotal merger - Mugglehead Magazine
atai Life Sciences to Participate in Upcoming Investor Conferences - Yahoo
2 ‘Strong Buy’ Psychedelic Stocks To Scoop Up ASAP - Barchart.com
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors - Benzinga
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know - Nasdaq
atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy? - sharewise
Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year? - Yahoo Finance
atai Life Sciences holds annual general meeting - Investing.com Australia
atai Life Sciences holds annual general meeting By Investing.com - Investing.com India
ATAI Life Sciences Approves Key Governance Changes - TipRanks
Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies - Yahoo Finance
ATAI Life Sciences Sees Significant Rise in Borrow Rate | ATAI S - GuruFocus
Atai Life Sciences N V Azioni (ATAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atai Life Sciences N V Azioni (ATAI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kirpekar Sahil | Chief Business Officer |
Mar 21 '25 |
Sale |
1.35 |
48,563 |
65,560 |
115,636 |
| Craig Kevin James | Chief Medical Officer |
Mar 21 '25 |
Sale |
1.35 |
11,563 |
15,610 |
8,437 |
| Rao Srinivas | See Remarks |
Mar 21 '25 |
Sale |
1.35 |
75,418 |
101,814 |
212,942 |
| Johnson Anne Nagengast | Chief Financial Officer |
Mar 21 '25 |
Sale |
1.35 |
33,545 |
45,286 |
140,045 |
| Short Glenn Frank | Chief Scientific Officer |
Mar 21 '25 |
Sale |
1.35 |
13,161 |
17,767 |
42,333 |
0.78%
1.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):